128 related articles for article (PubMed ID: 38140926)
1. Prognostic Value of the Glasgow Prognostic Score in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Meta-Analysis.
Wang H; Yang R; Cheng C; Wang S; Liu D; Li W
Nutr Cancer; 2024; 76(2):187-195. PubMed ID: 38140926
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer.
Zhang Y; Chen S; Chen H; Li W
Cancer Med; 2023 Jan; 12(1):38-48. PubMed ID: 35702873
[TBL] [Abstract][Full Text] [Related]
3. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen H; Han KD; He ZJ; Huang YS
Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis.
Zhou K; Cao J; Lin H; Liang L; Shen Z; Wang L; Peng Z; Mei J
Front Oncol; 2022; 12():962173. PubMed ID: 36059629
[TBL] [Abstract][Full Text] [Related]
5. Pre-treatment Glasgow prognostic score and modified Glasgow prognostic score may be potential prognostic biomarkers in urological cancers: a systematic review and meta-analysis.
Qi F; Xu Y; Zheng Y; Li X; Gao Y
Ann Transl Med; 2019 Oct; 7(20):531. PubMed ID: 31807513
[TBL] [Abstract][Full Text] [Related]
6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
7. Association between pretreatment C-reactive protein level and survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Wang H; Yang R; Zhou K; Wang S; Cheng C; Liu D; Li W
Int Immunopharmacol; 2023 Nov; 124(Pt B):110937. PubMed ID: 37757636
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of the Glasgow prognostic score in lung cancer: evidence from 10 studies.
Jin J; Hu K; Zhou Y; Li W
Int J Biol Markers; 2018 May; 33(2):201-207. PubMed ID: 29076522
[TBL] [Abstract][Full Text] [Related]
9. Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
Li N; Zheng X; Gan J; Zhuo T; Li X; Yang C; Wu Y; Qin S
Chin Med J (Engl); 2023 Nov; 136(21):2562-2572. PubMed ID: 37925595
[TBL] [Abstract][Full Text] [Related]
10. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.
Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis.
Wang H; Li C; Yang R; Jin J; Liu D; Li W
PLoS One; 2022; 17(5):e0268288. PubMed ID: 35522679
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis.
Yang T; Hao L; Yang X; Luo C; Wang G; Lin Cai C; Qi S; Li Z
BMJ Open; 2021 Sep; 11(9):e049123. PubMed ID: 34475167
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang Z; Li Y; Yan X; Song Q; Wang G; Hu Y; Jiao S; Wang J
Cancer Med; 2019 Apr; 8(4):1467-1473. PubMed ID: 30848091
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of
Ling T; Zhang L; Peng R; Yue C; Huang L
Front Immunol; 2022; 13():1014063. PubMed ID: 36466905
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Li LL; Yu CF; Xie HT; Chen Z; Jia BH; Xie FY; Cai YF; Xue P; Zhu SJ
Cancer Med; 2023 May; 12(10):11211-11233. PubMed ID: 37161541
[TBL] [Abstract][Full Text] [Related]
17. Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis.
Yu S; Zhang S; Xu H; Yang G; Xu F; Yang L; Chen D; An G; Wang Y
BMJ Open; 2023 Mar; 13(3):e059457. PubMed ID: 36931679
[TBL] [Abstract][Full Text] [Related]
18. Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: A comprehensive systematic review and meta-analysis.
Deng HY; Chen ZJ; Qiu XM; Zhu DX; Tang XJ; Zhou Q
Nutrition; 2021 Oct; 90():111345. PubMed ID: 34166897
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
Yan BD; Cong XF; Zhao SS; Ren M; Liu ZL; Li Z; Chen C; Yang L
Curr Cancer Drug Targets; 2019; 19(3):199-209. PubMed ID: 29714142
[TBL] [Abstract][Full Text] [Related]
20. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A
Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]